All posts by medical

Hematology Therapies Market Growth to Witness Uptrend with Robust Sales Volume – Cole of Duty

AMA Research have added latest edition of survey study on Global Hematology Therapies Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for Global Hematology Therapies Forecast till 2025*. Some are the key players taken under coverage for this study is Abbott Laboratories (United States), Bio-Rad Laboratories (United States), Roche (Switzerland), HORIBA (Japan), Beckman Coulter (United States), Bayer (Germany), Sysmex Corporation (Japan), Ortho Clinical Diagnostic (United States), Siemens Healthineers (Germany), Boule Diagnostics (Sweden), EKF Diagnostics (United Kingdom) and Mindray Medical (China)..

Free Sample Report + All Related Graphs & Charts @ https://www.advancemarketanalytics.com/sample-report/128606-global-hematology-therapies-market

Hematologic therapies represent a molecular understanding of the disease pathophysiology and treatment targeted precisely at the known aberration. Hematology includes the treatment of blood disorders and malignancies, like leukemia, hemophilia, lymphoma and sickle-cell anemia. Hematology is a branch of internal medicine that deals with the diagnosis, physiology, prognosis, pathology, etiology, treatment, and prevention of blood-related disorders. Hematologists focus mainly on lymphatic organs and bone marrow and may diagnose blood count irregularities or platelet irregularities.

Important Features that are under offering & key highlights of the report:

1) How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020?

Analyst at AMA are constantly gathering and conducting survey with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to evaluate study and market estimates. Due to lockdown different online medium and procedures are followed like Survey Monkey, LinkedIn Connections, and Email reach and industry forum to established industry viewpoint to garner rich insights for study. A special chapter in the study presents Impact Analysis of COVID-19 on Global Hematology Therapies Market along with tables and graphs related to various country and segments showcasing impact on growth trends.

2) Can list of players be customizing according to targeted regional geographies to match business objective?

Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are Abbott Laboratories (United States), Bio-Rad Laboratories (United States), Roche (Switzerland), HORIBA (Japan), Beckman Coulter (United States), Bayer (Germany), Sysmex Corporation (Japan), Ortho Clinical Diagnostic (United States), Siemens Healthineers (Germany), Boule Diagnostics (Sweden), EKF Diagnostics (United Kingdom) and Mindray Medical (China).. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography.

** List of companies covered may vary in the final report subject to Name Change / Merger & Acquisition Activity etc. based on the difficulty of survey since data availability needs to be confirmed by research team especially in case of privately held company. Up to 2 players can be added at no additional cost.

3) Can Market be broken down by different set of application and types?

Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.

** 3+ Additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of AMA based on the requirement shared and accordingly deliverable time will also be disclosed.

Enquire for customization in Report @https://www.advancemarketanalytics.com/enquiry-before-buy/128606-global-hematology-therapies-market

To comprehend Hematology Therapies market dynamics in the world mainly, the worldwide Hematology Therapies market is analyzed across major global regions. AMA also provides customized specific regional and country-level reports for the following areas.

Get Reasonable Discount on This Premium Report @ https://www.advancemarketanalytics.com/request-discount/128606-global-hematology-therapies-market

Major Highlights of TOC:

Chapter One: Market Overview

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD1000

Market Drivers, Market Challenges, Market Trends, Restraints & Opportunities, Post Covid Scenario

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Bargain Power

Chapter Five: Global Hematology Therapies, by Market Segmentation and Geography (value, volume**) (2014-2019) USD1400

by Type (Instruments, Consumable), Application (Physiology, Pathology, Etiology, Diagnosis, Treatment, Prognosis), Blood Disorder Type (Hemophilia, Leukemia, Lymphoma, Sickle-Cell Anemia, Others), End-User (Diagnostic Laboratories, Hospitals and Clinics, Academic Institutes, Research Laboratory, Others)

.

.

Global Hematology Therapies Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Hematology Therapies Manufacturers/Players Analysis USD1200

Competitive Landscape, Comparative Market Share Analysis (2018-2019), Peer Group Analysis (2019), BCG Matrix, Company Profile, Product/Service Offering Matrix

Chapter Seven: Global Hematology Therapies, by Market Segmentation and Region (value, volume**) (2020-2025) USD1400

Sections same as Chapter Five

Chapter Eight:Company profiles / Competitive Landscape [12 Players] USD1250

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicableActual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

AMA also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise section or region wise report like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)

AMA Research & Media LLP

Unit No. 429, Parsonage Road Edison, NJ

New Jersey USA 08837

Phone: +1 (206) 317 1218

[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

View post:
Hematology Therapies Market Growth to Witness Uptrend with Robust Sales Volume - Cole of Duty

COVID-19 Effect On Biostimulants Market Share and Development 2020 – Cole of Duty

Overview Of Biostimulants Industry 2020-2026:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Biostimulants Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Agricultural biostimulants include diverse formulations of compounds, substances and other products that are applied to plants or soils to regulate and enhance the crops physiological processes, thus making them more efficient. Biostimulants act on plant physiology through different pathways than nutrients to improve crop vigour, yields, quality and post-harvest shelf life/conservation.

Biostimulants Market competition by top manufacturers as follow: , Agri Life, Biostadt, Neophyll, Nakoda Biocontrols, Biotech International, India FarmCare, Miracle Organics Private, HCM Agro produts, Vijay Agro Industries, Arysta Life Science, VALAGRO, Leili, Acadian Seaplants, Kelpak, Grow More

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/11841

The global Biostimulants market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Acid-based BiostimulantsExtract-based Biostimulants

Market Segment by Applications, covers:Fruits & VegetablesTurf & OrnamentalsRow Crops

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/11841

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Biostimulants-Market-11841

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Visit link:
COVID-19 Effect On Biostimulants Market Share and Development 2020 - Cole of Duty

Swedish Healthcare Region to Realize Integrated Diagnostics – Expands IT Solution From Sectra With Digital Pathology – BioSpace

LINKPING, Sweden, June 29, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a digital pathology contract with Region Vstmanland in Sweden. The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department. Using the same system to store and view images and information from various diagnostic specialties enables integrated diagnostics, which is key for efficient cancer care.

"We are excited to take the next step in our digitization journey toward a truly integrated diagnostic workflow. It is important that we can scale our solution at our own pace and Sectra's solution allows this. We are also looking forward to equipping our pathologists with the tools that support us in our efforts to provide the best possible cancer care," says Jonas Cederberg, Chair of Department for Medical Diagnostics at Region Vstmanland.

With digital images of tissue samples rather than physical glass slides, pathologists can instantly access and share current and historical images and information from anywhere and at any time. Digital pathology provides pathologists with tools that are not available when using a microscope, which reduces variation between examinations and enables pathologists to spend their time on more advanced tasks. The digital solution also provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements. Furthermore, digital access facilitates second opinions, external reading resources, and specialist consultations.

Sectra's digital pathology solution will be integrated with Region Vstmanland's laboratory information system (LIS). This will provide pathologists with a complete overview of the patient history in one application and enable workflow orchestration to drive the workflow according to sub-specialties, rules and priorities. The solution's vendor-neutral approach also gave Region Vstmanland the freedom to select the scanner vendor of its choice.

Region Vstmanland is already using Sectra's solution for handling medical images within radiology, mammography, and clinical physiology. The solution will now also include approximately 10,000 pathology examinations per year, with the opportunity to gradually increase usage. The agreement to expand the existing contract was signed in May 2020.

Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Read more about Sectra's enterprise imaging solution and why Sectra PACS is ranked "Best in KLAS" for seven consecutive years at https://medical.sectra.com/.

About SectraSectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linkping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2019/2020 fiscal year totaled SEK 1,661 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit https://sectra.com/.

CONTACT:

For further information, please contact:Dr. Torbjrn KronanderCEO and President Sectra AB+46-(0)705-23-52-27

Marie Ekstrm TrgrdhExecutive Vice President Sectra AB and President Sectra Imaging IT Solutions+46-(0)708-23-56-10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/swedish-healthcare-region-to-realize-integrated-diagnostics-expands-it-solution-from-sectra-with-dig,c3142885

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/swedish-healthcare-region-to-realize-integrated-diagnostics---expands-it-solution-from-sectra-with-digital-pathology-301084853.html

SOURCE Sectra

Company Codes: Stockholm:SECTB, ISIN:SE0012853661, RICS:SECTB.ST, LSE:0A0L, Stuttgart:ECRH

Link:
Swedish Healthcare Region to Realize Integrated Diagnostics - Expands IT Solution From Sectra With Digital Pathology - BioSpace

Genetics, profession: Heres the reason why eczema happens – Hindustan Times

Researchers may be getting closer to finding the cure of a chronic skin condition - Eczema, by analysing the cause of the skin disease in a recent study.

An estimated 35 million Americans suffer from eczema, also known as atopic dermatitis. Worldwide, 2 to 5 % of adults and about 15 % of children suffer from symptoms such as dry, inflamed and very itchy skin with open sores.

Although there are myriad treatments for eczema, such as medical creams and natural remedies, the exact causes of the condition remain elusive.

In a new paper, the team -- Associate Professor Guy German and PhD student Zachary W. Lipsky from the Thomas J. Watson School of Engineering and Applied Sciences Department of Biomedical Engineering, and Associate Professor Claudia N.H. Marques of the Harpur College of Arts and Sciences Department of Biological Sciences -- connects two aspects of eczema research that are rarely studied together.

One result of atopic dermatitis is a decreased level of skin oils known as lipids, particularly one group called ceramides. Lipids on the surface of the skin function to regulate hydration and also help defend the skin from foreign invaders either indirectly through immune signalling or directly through their inherent antimicrobial activity.

Another result of eczema is an increase in staph bacteria in the skin, which can cause irritation and infection.

German said that genetics can play a part in whether someone has eczema, but people in certain occupations have also been shown to be more likely to get the skin condition, such as healthcare professionals, metalworkers, hairdressers, and food processing workers. The connection? An increased amount of handwashing or regular contact with detergents for your job.

What happens if, either through a mutation or through occupational risks, theres a decreased presence of lipids on the skin? he said.

The essence of this study is that in normal, healthy conditions, bacteria do not penetrate the skin barrier. In atopic dermatitis conditions or lipid levels consistent with AD, it does -- and it consistently takes nine days, he added.

Because the staph bacteria are immobile, they need to multiply in number to grow through the protective outer skin layer known as the stratum corneum. The Watson researchers believe the bacteria dont grow around the skin cells but actually through them. With lipid depletion -- either through genetics or occupational risks -- the skin appears to become more vulnerable to bacterial invasion and infection of underlying skin tissue.

When we usually think about the oils in our skin, we think about water retention and moisturizing -- things like that. Now were looking at how these lipids are important for protection against these microorganisms that can come in and cause diseases, Lipsky said.

While this study has not unlocked all the secrets of atopic dermatitis, showing that the bacteria could be the cause rather than the result of the disease is a major step forward. Further research is required, and thats where the Watson team will investigate next.

Now that we know that bacteria can permeate through lipid depleted skin, how does it affect the skin mechanically? Does it make the skin weaker and more likely to crack? Can we figure out how bacteria are moving through different skin layers? Lipsky said.

In scientific research, you get one answer and three additional questions pop up, so were never stuck for things to do, German added.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter

The rest is here:
Genetics, profession: Heres the reason why eczema happens - Hindustan Times

New Genetic Mutations Linked to ASD – Technology Networks

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Radboud University Medical Center in the Netherlands have identified mutations in a gene called CNOT1 that affect brain development and impair memory and learning. The study is the first to link neurodevelopmental delays with CNOT1, suggesting that drugs that help restore the genes function may have therapeutic benefit. The research, published in The American Journal of Human Genetics, also revealed that CNOT1 interacts with several known autism spectrum disorder (ASD) genes, opening new research avenues for the condition.Prior to this work, the CNOT1 gene was not on the radar of autism researchers, says Rolf Bodmer, Ph.D., director and professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys and the studys co-corresponding and co-senior author. This discovery could help us better understand the genetic mechanisms underlying ASD. Our work is also a first step toward exploring drugs that could augment the function of CNOT1 and might be able to help children with neurodevelopmental delays who have these specific mutations.

The cause of developmental disabilities, including ASD, is poorly understood. Research indicates that there may be a genetic component to these conditions, but the precise impact of the genetic variations that have been uncovered to date is unclear. Identifying the underlying cause of developmental disabilities would allow scientists to create diagnostic tests that would provide early diagnoses and potential treatments.

To answer this question, the researchers at Radboud University turned to Bodmer, a world-renowned genetics expert who studies how genes contribute to disease using a fruit fly model. Sreehari Kalvakuri, Ph.D., a postdoctoral researcher in the Bodmer lab, created fruit flies that contained the same CNOT1 variations seen in the patients, including DNA sequences that were misspelled (missense), cut short (truncated) or otherwise altered.

This work identified nine CNOT1 variants that impaired learning and memory, which was measured by several independent approaches including a courtship assay that tested the ability of male fruit flies to remember if their female partners had paired with other males. All of these variants appeared spontaneously (de novo) in the patients, meaning they were not inherited. The scientists also discovered that these CNOT1 mutations interact with known ASD genes revealing a genetic link to ASD that can be further explored.

Fruit flies are a great biological model because we can complete genetic studies very quickly. This work only took a few months instead of the potential decade using a mouse model, says Kalvakuri, the studys co-first author. Additionally, the CNOT1 gene is highly conserved between fruit flies and humans, meaning it does not change much, so we are optimistic these findings can be extrapolated to people.

Next, the scientists plan to identify which molecular components interact with CNOT1, which functions as a scaffold that builds up a larger protein complex. This work might uncover additional potential drug targets for intellectual, learning or memory disorders, including ASD.

The first step toward helping children with neurodevelopmental delays is to determine the cause of the condition, says Bodmer. Our ultimate hope is to find a treatment that could be given as early as possible to help these children stay on track developmentally.

Surprisingly, the findings also have implications for heart disease, the primary focus of Bodmers lab.

A significant fraction of these patients also have cardiac defects, says Bodmer. Conversely, children who are born with heart defects are at a higher risk of developing ASD, too. This study on CNOT1 also provides a previously unknown genetic link between heart function and ASD.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Follow this link:
New Genetic Mutations Linked to ASD - Technology Networks

Open Rank Faculty Positions in Plant Quantitative Genetics and Breeding job with SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY | 211940 – Times Higher…

Skoltech is seeking application for tenure track faculty at Assistant Professor or Associate Professor position to its newly createdDigital Agriculture Laboratory.Thecandidate should hold a PhD degree (or equivalent) inbiology, genetics, biotechnology.He/she should have substantial expertise inplant genetics, genomics or other related disciplines, proven experience of establishing independent sustainable research, educational and innovation programs, in conjunction with established MS and PhD programs in Life Sciences. Of particular interest are those candidates with proven expertise in plant quantitative genetics, plant breeding and agrobiotech.

The Skolkovo Institute of Science and Technologyis an English-speaking international graduate research university in Moscow, Russia. Established in 2011 in collaboration with MIT, Skoltech advances scientific knowledge, educates global leaders in innovation and fosters new technologies to address critical issues facing Russia and the world. Skoltech is an integral part of theSkolkovo Innovation Centerthat comprises a complete high-tech city with a number of international R&D centers and start-up incubators.

The mission of the Digital Agriculture Laboratory is to conduct research, education, and innovation activities to provide new tools and techniques for implementing modern breeding techniques in plants and animals and to address the question of digital agriculture. We aim to establish at Skoltech a highly impactful interdisciplinary center of fundamental and problem-driven research aimed at advancing our knowledge and innovations in the agriculture sector, with particular dedication to the relationships with industrial partners.

How to apply:

To apply, please go to our application website: http://join.skoltech.ru/how-to-apply/ and follow the instructions or send an e-mail tofacultysearch@skoltech.ru.

Review of applications will continue until the position has been filled. Applicants should submit the following documents: (1) cover letter, (2) curriculum vitae, (3) two-page statement of teaching interests and philosophy, (4) statement of research plans, (5) innovation statement, and (6) the names and contact information of at least three professional references.

The application submission deadline isSeptember 1st. The selection of candidates for the position starts immediately until the position is filled.

Skoltech offers:

Skoltech is committed to diversity and equality, and all applicants are invited to apply regardless of their gender, race or nationality.

Read more from the original source:
Open Rank Faculty Positions in Plant Quantitative Genetics and Breeding job with SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY | 211940 - Times Higher...

Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer -…

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review [95% Confidence Interval: 15.9%-33.3%] with a median duration of response (DOR) of 8.3 months. The most common treatment-related adverse events (greater than or equal to 20 percent) included alopecia, epistaxis (nose bleeds), nausea, conjunctivitis, fatigue and dry eye. The data will be submitted for presentation at an upcoming medical meeting.

Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) directed to tissue factor, which is expressed on cervical cancer and can promote tumor growth, angiogenesis and metastases.1 Standard therapies for previously treated recurrent and/or metastatic cervical cancer generally result in limited objective response rates of typically less than 15 percent with median overall survival ranging from 6.0 to 9.4 months, in an all-comers population.1-8 Tisotumab vedotin is being developed by Seattle Genetics in collaboration with Genmab.

Available therapies upon progression after first line chemotherapy in recurrent or metastatic cervical cancer are limited, and there is a significant unmet need for new treatment options, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. Tisotumab vedotin has demonstrated clinically meaningful and durable objective responses with a manageable safety profile, and we look forward to discussing with the FDA the potential submission of a Biologics License Application to support an accelerated approval.

Cervical cancer originates in the cells lining the cervix. Over 13,500 women are expected to be diagnosed with cervical cancer in the U.S. in 2020, with approximately 4,200 deaths.9 Cervical cancer remains one of the leading causes of cancer death in women globally, with over 311,000 women dying annually; the vast majority of these women being in the developing world.10 Routine medical examinations and the human papillomavirus (HPV) vaccine have lowered the incidence of cervical cancer in the developed world. Despite these advances, women are still diagnosed with cervical cancer, which often recurs or becomes metastatic.

Additional clinical trials of tisotumab vedotin are currently enrolling patients, including in combination with pembrolizumab, carboplatin or bevacizumab, and with a weekly dosing schedule in patients with locally advanced or metastatic cervical cancer. Tisotumab vedotin is also being evaluated in other tissue factor expressing tumor types, including ovarian and other solid tumors.

About innovaTV 204 Trial

The innovaTV 204 trial (also known as GCT1015-04 or innovaTV 204/GOG-3023/ENGOT-cx6) is an ongoing single-arm, global, multicenter study of tisotumab vedotin for patients with recurrent or metastatic cervical cancer who were previously treated with doublet chemotherapy with or without bevacizumab. Additionally, patients were eligible if they had received up to two prior lines of therapy in the metastatic setting. In the study, 101 patients were treated with tisotumab vedotin at multiple centers in the U.S. and Europe. The primary endpoint of the trial was confirmed objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by independent central review. Key secondary endpoints included duration of response, progression-free survival, overall survival, safety and tolerability.

The study was conducted in collaboration with European Network of Gynaecological Oncological Trial Groups (ENGOT) and Gynecologic Oncology Group (GOG). For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit http://www.clinicaltrials.gov.

About Tisotumab Vedotin

Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) composed of Genmabs fully human monoclonal antibody specific for tissue factor and Seattle Genetics ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody and releases it upon internalization, inducing target cell death. In cancer biology, tissue factor is a protein that can promote tumor growth, angiogenesis and metastases.1 Based on its high expression on many solid tumors and its rapid internalization, tissue factor was selected as a target for an ADC approach. Tisotumab vedotin is being co-developed by Genmab and Seattle Genetics, under an agreement in which the companies share all costs and profits for the product on a 50:50 basis.

Tisotumab vedotin is being evaluated in ongoing clinical trials as monotherapy in a range of solid tumors, including recurrent and/or metastatic cervical cancer, ovarian cancer and in combination with other commonly used therapies in recurrent or metastatic cervical cancer. These trials are evaluating tisotumab vedotin on a weekly or every three weeks dosing schedule.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential submission of a BLA to the FDA under the FDAs accelerated approval program and the potential for regulatory approval of tisotumab vedotin based on the innovaTV 204 trial; the therapeutic potential of tisotumab vedotin, its possible benefits and uses, including as monotherapy or in combination with other agents, and in other tumor types or with a weekly dosing regimen, and the tisotumab vedotin future development program. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that the data from innovaTV 204 may not be sufficient to support accelerated approval; the possibility of impediments or delays in the submission of a potential BLA to the FDA; the risk of adverse events, including the potential for newly-emerging safety signals; delays, setbacks or failures in clinical development activities for a variety of reasons, including the difficulty and uncertainty of pharmaceutical product development, adverse regulatory action, possible required modifications to clinical trials, failure to properly conduct or manage clinical trials and failure of clinical results to support continued development or regulatory approvals. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

References:

1 Van de Berg YW et al. Blood 2012;119:924.2 Miller et al., Gynecol Oncol 2008; 110:65.3 Bookman et al., Gynecol Oncol 2000; 77:446.4 Garcia et al., Am J Clin Oncol 2007; 30:428.5 Monk et al., J Clin Oncol 2009; 27:1069.6 Santin et al., Gynecol Oncol 2011; 122:495.7 Schilder et al., Gynecol Oncol 2005; 96:1038 Chung HC et al. J Clin Oncol 2019; 37:1470.9 National Cancer Institute SEER. Cancer Stat Facts: Cervix Uteri Cancer. Available at https://seer.cancer.gov/statfacts/html/cervix.html. Last accessed April 2020.10 Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 countries https://www.iarc.fr/news-events/global-cancer-statistics-2018-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries/.

Visit link:
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer -...

Race Is Real, But It’s Not Genetic – Discover Magazine

A friend of mine with Central American, Southern European and West African ancestry islactose intolerant. Drinking milk products upsets her stomach, and so she avoids them. About a decade ago, because of her low dairy intake, she feared that she might not be getting enough calcium, so she asked her doctor for abone density test. He responded that she didnt need one because blacks do not get osteoporosis.

My friend is not alone. The view that black people dont need a bone density test is a longstanding and common myth. A2006 studyin North Carolina found that out of 531 African American and Euro-American women screened for bone mineral density, only 15 percent were African American women despite the fact that African American women made up almost half of that clinical population. A health fair in Albany, New York, in 2000,turned into a ruckuswhen black women were refused free osteoporosis screening. The situationhasnt changed muchin more recent years.

Meanwhile,FRAX, a widely used calculatorthat estimates ones risk of osteoporotic fractures, is based on bone density combined with age, sex and, yes, race. Race, even though it is never defined or demarcated, is baked into the fracture risk algorithms.

Lets break down the problem.

First, presumably based on appearances, doctors placed my friend and others into a socially defined race box called black, which is a tenuous way to classify anyone.

Race is a highly flexible way in which societies lump people into groups based on appearance that is assumed to be indicative of deeper biological or cultural connections. As a cultural category, the definitions and descriptions of races vary. Color lines based on skin tone can shift, which makes sense, but the categories are problematic for making any sort of scientific pronouncements.

Second, these medical professionals assumed that there was a firm genetic basis behind this racial classification, which there isnt.

Third, they assumed that this purported racially defined genetic difference would protect these women from osteoporosis and fractures.

Some studies suggestthat African American women meaning women whose ancestry ties back to Africa may indeed reach greater bone density than other women, which could be protective against osteoporosis. But that does not mean being black that is, possessing an outward appearance that is socially defined as black prevents someone from getting osteoporosis or bone fractures. Indeed, this same research also reports that African American women are more likely to die after a hip fracture. The link between osteoporosis risk and certain racial populations may be due to lived differencessuch as nutritionandactivity levels, both of which affect bone density.

But more important:Geographicancestry is not the same thing as race. African ancestry, for instance, does not tidily map onto being black (or vice versa). In fact, a2016 studyfound wide variation in osteoporosis risk among women living in different regions within Africa. Their genetic risks have nothing to do with their socially defined race.

When medical professionals or researchers look for ageneticcorrelateto race, they are falling into a trap: They assume thatgeographic ancestry, which does indeed matter to genetics, can be conflated with race, which does not. Sure, different human populations living in distinct places may statistically have different genetic traits such as sickle cell trait (discussed below) but such variation is aboutlocal populations(people in a specific region), not race.

Like a fish in water, weve all been engulfed by the smog of thinking that race is biologically real. Thus, it is easy to incorrectly conclude that racial differences in health, wealth and all manner of other outcomes are the inescapable result of genetic differences.

The reality is that socially defined racial groups in the U.S. and most everywhere else do differ in outcomes. But thats not due to genes. Rather, it is due to systemic differences in lived experience and institutional racism.

Communities of color in the United States, for example, often have reduced access to medical care, well-balanced diets andhealthy environments. They are often treated more harshly in their interactions withlaw enforcement and the legal system. Studies show that they experience greater social stress, includingendemic racism, that adversely affects all aspects of health. For example, babies born to African American women are more thantwice as likely to diein their first year than babies born to non-Hispanic Euro-American women.

Systemic racism leads to different health outcomes for various populations. The infant mortality rate, for example, for African American infants is double that for European Americans. (Credit: Kelly Lacy/Pexels)

As a professor of biological anthropology, I teach and advise college undergraduates. While my students are aware of inequalities in the life experiences of different socially delineated racial groups, most of them also think that biological races are real things. Indeed, more than half of Americans still believe that their racial identity is determined byinformation contained in their DNA.

For the longest time, Europeans thought that the sun revolved around the Earth. Their culturally attuned eyes saw this as obvious and unquestionably true. Just as astronomers now know thats not true,nearly all population geneticistsknow that dividing people into races neither explains nor describes human genetic variation.

Yet this idea of race-as-genetics will not die. For decades, it has been exposed to the sunlight of facts, but, like a vampire, it continues to suck blood not only surviving but causing harm in how it can twist science to support racist ideologies. With apologies for the grisly metaphor, it is time to put a wooden stake through the heart of race-as-genetics. Doing so will make for better science and a fairer society.

In 1619, the first people from Africa arrived in Virginia and became integrated into society. Only after African and European bond laborers unified in various rebellions did colony leaders recognize the need to separate laborers.Race dividedindentured Irish and other Europeans from enslaved Africans, and reduced opposition by those of European descent to the intolerable conditions of enslavement. What made race different from other prejudices, including ethnocentrism (the idea that a given culture is superior), is that it claimed that differences were natural, unchanging and God-given. Eventually, race also received the stamp of science.

Over the next decades, Euro-American natural scientists debated the details of race, asking questions such as how often the races were created (once, as stated in the Bible, or many separate times), the number of races and their defining, essential characteristics. But they did not question whether races were natural things. They reified race, making the idea of race real by unquestioning, constant use.

In the 1700s, Carl Linnaeus, the father of modern taxonomy and someone not without ego, liked to imagine himself asorganizing what God created. Linnaeus famously classified ourown species into racesbased on reports from explorers and conquerors.

The race categories he created includedAmericanus,Africanus, and evenMonstrosus(for wild and feral individuals and those with birth defects), and their essential defining traits included a biocultural mlange of color, personality and modes of governance. Linnaeus describedEuropeausas white, sanguine and governed by law, andAsiaticusas yellow, melancholic and ruled by opinion. These descriptions highlight just how much ideas of race are formulated by social ideas of the time.

Swedish taxonomist Carl Linnaeus divided humanity up into racial categories according to his notion of shared essences among populations, a concept researchers now recognize has no scientific basis. (Credit: Wikimedia Commons/Public Domain)

In line with early Christian notions, these racial types were arranged in a hierarchy:a great chain of being, from lower forms to higher forms that are closer to God. Europeans occupied the highest rungs, and other races were below, just above apes and monkeys.

So, the first big problems with the idea of race are that members of a racial group do not share essences, Linnaeus idea of some underlying spirit that unified groups, nor are races hierarchically arranged. A related fundamental flaw is that races were seen to be static and unchanging. There is no allowance for a process of change or what we now call evolution.

There have been lots of efforts since Charles Darwins time to fashion the typological and static concept of race into an evolutionary concept. For example, Carleton Coon, a former president of the American Association of Physical Anthropologists, argued inThe Origin of Races(1962) that five racesevolved separatelyand became modern humans at different times.

One nontrivial problem with Coons theory, and all attempts to make race into an evolutionary unit, is that there is no evidence. Rather, all the archaeological and genetic data point to abundant flows of individuals, ideas and genes across continents, withmodern humansevolving at the same time, together.

Afew pundits such asCharles Murrayof the American Enterprise Institute and science writers such asNicholas Wade, formerly ofThe New York Times, still argue that even though humans dont come in fixed, color-coded races, dividing us into races still does a decent job ofdescribinghuman genetic variation. Their position is shockingly wrong. Weve known for almost 50 years that race does not describe human genetic variation.

In 1972, Harvard evolutionary biologist Richard Lewontinhad the idea to testhow much human genetic variation could be attributed to racial groupings. He famously assembled genetic data from around the globe and calculated how much variation was statistically apportioned within versus among races. Lewontin found that only about 6 percent of genetic variation in humans could be statistically attributed to race categorizations. Lewontin showed that the social category of race explains very little of the genetic diversity among us.

Furthermore, recent studies reveal that the variation between any two individuals isverysmall, on the order of onesingle nucleotide polymorphism(SNP), or single letter change in our DNA, per 1,000. That means that racial categorization could, at most, relate to 6 percent of the variation found in 1 in 1,000 SNPs. Put simply, race fails to explain much.

In addition, genetic variation can be greaterwithingroups that societies lump together as one race than it is between races. To understand how that can be true, first imagine six individuals: two each from the continents of Africa, Asia and Europe. Again, all of these individuals will be remarkably the same: On average, only about 1 out of 1,000 of their DNA letters will be different. A study by Ning Yu and colleaguesplaces the overall difference more precisely at 0.88 per 1,000.

The researchers further found that people in Africa had less in common with one another than they did with people in Asia or Europe. Lets repeat that: On average, two individuals in Africa aremoregenetically dissimilar from each other than either one of them is from an individual in Europe or Asia.

Homo sapiensevolved in Africa; the groups that migrated out likely did not include all of the genetic variation that built up in Africa. Thats an example of what evolutionary biologists call thefounder effect, where migrant populations who settle in a new region have less variation than the population where they came from.

Genetic variation across Europe and Asia, and the Americas and Australia, is essentially a subset of the genetic variation in Africa. If genetic variation were a set of Russian nesting dolls, all of the other continental dolls pretty much fit into the African doll.

What all these data show is that the variation that scientists from Linnaeus to Coon to the contemporary osteoporosis researcher think is race is actually much better explained by a populationslocation. Genetic variation is highly correlated togeographic distance. Ultimately, the farther apart groups of people are from one another geographically, and, secondly, the longer they have been apart, can together explain groups genetic distinctions from one another. Compared to race, those factors not only better describe human variation, they invoke evolutionary processes to explain variation.

Those osteoporosis doctors might argue that even though socially defined race poorly describes human variation, it still could be a useful classification tool in medicine and other endeavors. When the rubber of actual practice hits the road, is race a useful way to make approximations about human variation?

When Ive lectured at medical schools, my most commonly asked question concerns sickle cell trait. Writer Sherman Alexie, a member of the Spokane-Coeur dAlene tribes, put the question this wayin a 1998 interview: If race is not real, explain sickle cell anemia to me.

OK! Sickle cell is a genetic trait: It is the result of an SNP that changes the amino acid sequence of hemoglobin, the protein that carries oxygen in red blood cells. When someone carries two copies of the sickle cell variant, they will have the disease. In the U.S., sickle cell disease is most prevalent in people who identify as African American, creating the impression that it is a black disease.

(Credit: SciePro/Shutterstock)

Yet scientists have known about the much more complexgeographic distributionof sickle cell mutation since the 1950s. It is almost nonexistent in the Americas, most parts of Europe and Asia and also in large swaths of Northern and Southern Africa. On the other hand, it is common in West-Central Africa and also parts of the Mediterranean, Arabian Peninsula, and India. Globally, it does not correlate with continents or socially defined races.

Inone of the most widely citedpapers in anthropology, American biological anthropologist Frank Livingstone helped to explain the evolution of sickle cell. He showed that places with a long history of agriculture and endemic malaria have a high prevalence of sickle cell trait (a single copy of the allele). He put this information together with experimental and clinical studies that showed how sickle cell trait helped people resist malaria, and made a compelling case for sickle cell trait being selected for in those areas.Evolution and geography, not race, explain sickle cell anemia.

What about forensic scientists: Are they good at identifying race? In the U.S., forensic anthropologists are typically employed by law enforcement agencies to help identify skeletons, including inferences about sex, age, height and race. The methodological gold standards for estimating race are algorithms based on a series of skull measurements, such as widest breadth and facial height. Forensic anthropologists assume these algorithms work.

The origin of the claim that forensic scientists are good at ascertaining race comes from a 1962 study of black, white and Native American skulls, which claimed an 8090 percent success rate. That forensic scientists are good at telling race from a skull is a standard trope of both thescientific literatureandpopular portrayals.But my analysisof four later tests showed that the correct classification of Native American skulls from other contexts and locations averaged about two incorrect for every correct identification. The results are no better than a random assignment of race.

Thats because humans are not divisible into biological races. On top of that, human variation does not stand still. Race groups are impossible to define in any stable or universal way. It cannot be done based on biology not by skin color, bone measurements or genetics. It cannot be done culturally: Race groupings have changed over time and place throughout history.

Science 101: If you cannot define groups consistently, then you cannot make scientific generalizations about them.

Skull measurements are a longstanding tool in forensic anthropology. (Credit: Internet Archive Book Images/Flickr/Public Domain)

Wherever one looks, race-as-genetics is bad science. Moreover, when society continues to chase genetic explanations, it misses the larger societal causes underlying racial inequalities in health, wealth and opportunity.

To be clear, what I am saying is that human biogenetic variation is real. Lets just continue to study human genetic variation free of the utterly constraining idea of race. When researchers want to discuss genetic ancestry or biological risks experienced by people in certain locations, they can do so without conflating these human groupings withracial categories. Lets be clear that genetic variation is an amazingly complex result of evolution and mustnt ever be reduced to race.

Similarly, race is real, it just isnt genetic. Its a culturally created phenomenon. We ought to know much more about the process of assigning individuals to a race group, including the category white. And we especially need to know more about the effects of living in a racialized world: for example, how a societys categoriesand prejudiceslead to health inequalities. Lets be clear that race is a purely sociopolitical construction with powerful consequences.

It is hard to convince people of the dangers of thinking race is based on genetic differences. Like climate change, the structure of human genetic variation isnt something we can see and touch, so it is hard to comprehend. And our culturally trained eyes play a trick on us by seeming to see race as obviously real. Race-as-genetics is even more deeply ideologically embedded than humanitys reliance on fossil fuels and consumerism. For these reasons, racial ideas will prove hard to shift, but it is possible.

Over 13,000 scientistshave come together to form and publicize a consensus statement about the climate crisis, and that has surely moved public opinion to align with science. Geneticists and anthropologists need to do the same for race-as-genetics. The recent American Association of Physical AnthropologistsStatement on Race & Racismis a fantastic start.

In the U.S., slavery ended over 150 years ago and the Civil Rights Law of 1964 passed half a century ago, but the ideology of race-as-genetics remains. It is time to throw race-as-genetics on the scrapheap of ideas that are no longer useful.

We can start by getting my friend and anyone else who has been denied that long-overdue bone density test.

Alan Goodmanis a professor of biological anthropology at Hampshire College in Massachusetts. This story was originally posted onSAPIENS. Read the original articlehere.

Continued here:
Race Is Real, But It's Not Genetic - Discover Magazine

BRIEF-Seattle Genetics Announces Positive Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin – Reuters

June 29 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

* SEATTLE GENETICS - LOOK FORWARD TO DISCUSSING WITH FDA POTENTIAL SUBMISSION OF BLA TO SUPPORT ACCELERATED APPROVAL OF TISOTUMAB VEDOTIN Source text for Eikon: Further company coverage:

Link:
BRIEF-Seattle Genetics Announces Positive Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin - Reuters

University of East London lecturer says PHE report fails to address genetics – Newham Recorder

Video

PUBLISHED: 10:00 29 June 2020

Cash Boyle

Dr Winston Morgan, Reader in Toxicology and Clinical Biochemistry at the University of East London, says race and genetics are key omissions from the PHE report on coronavirus. Picture: University of East London

Archant

Email this article to a friend

To send a link to this page you must be logged in.

Dr Morgan a reader in toxicology and clinical biochemistry at the university commended the report for properly addressing the structural problems linked to racism which have caused Covid-19 to disproportionately impact BAME communities.

However, the lecturer criticised the complete lack of consideration given to the issue of genetics, and specifically to answering the question as to whether certain traits increase virus susceptibility.

Failing to adequately address this subject leaves the door open for continued speculation around race and genetics, said Dr Morgan.

This report was an opportunity to knock the speculation on its head, and allow for focus to be appropriately shifted to dealing with the damaging structural problems within society.

A spokesperson for PHE said: The review was not able to look at genetic factors and more research in this area is needed.

To complement the review, a research call by the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) has jointly called for research proposals to investigate emerging evidence of an association between ethnicity and COVID-19 incidence and adverse health outcomes.

Dr Morgan also queried how the report framed its discussion of the relationship between the BAME community and the NHS: The report missed a number of opportunities, such as not to consider that historical racism will impact on both the speed and level of treatment BAME groups are likely to receive when they interact with the NHS.

Instead, it focused on the fact that as a result of historical racism BAME groups are less likely to seek care when needed.

Both arguments are underpinned by historical racism, and should have been given equal weight in the report: By omitting the former it has the feel of blaming the victims for not complaining.

PHE conceded that the report did not consider every issue: There are many impacts of systemic racism and PHEs qualitative report identified the issues that were raised repeatedly by stakeholders.

This does not mean that other factors are not relevant and confirms the need for further more detailed research studies on these issues.

Dr Morgan concluded that despite reservations over the lack of wider recommendation about tackling structural racism in wider society, all seven recommendations should be implemented.

If you value what this story gives you, please consider supporting the Newham Recorder. Click the link in the orange box below for details.

More here:
University of East London lecturer says PHE report fails to address genetics - Newham Recorder